Specialty pharmaceutical company Avenacy has announced the US launch of its first Lidocaine Hydrochloride Injection, USP, according to an August 25, 2025, press release from the company. The product, which is indicated for the delivery of local or regional anesthesia or analgesia, is a generic equivalent of Xylocaine® as approved by the US Food and Drug Administration. The 1% Lidocaine HCl Injection, USP will be available in cartons containing 25 multidose vials (500 mg per 50 mL) and will feature Avenacy’s highly differentiated packaging and labeling. This supports accurate medication selection, aligning with the company’s commitment to championing patient safety and streamlining patient care.
“In just under two years, we’ve built a broad portfolio of critical injectable medications, and the launch of our first Lidocaine product represents an important step toward establishing Avenacy as a long-term supplier in this essential category,” says Jeff Yordon, co-founder and CEO of Avenacy. “Given the need for this product across a variety of procedures, we plan to continue expanding our Lidocaine offerings over the next year to support provider needs across multiple clinical settings.”
Avenacy, which is supported by a global network of development and contract manufacturing partners that have undergone successful FDA inspections based on cGMP standards, will begin shipping Lidocaine HCl, USP Injection to its wholesale partners later this week. The press release notes that US sales of 1% Lidocaine HCl Injection, USP 500 mg per 50 mL were approximately $6.9 million for the twelve months ending in June 2025.
